Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Frakefamide

From Wikipedia, the free encyclopedia
Opioid agonist peptide compound
Pharmaceutical compound
Frakefamide
Clinical data
Other namesL-Tyrosyl-D-alanyl-4-fluoro-L-phenylalanyl-L-phenylalaninamide
ATC code
  • None
Identifiers
  • (2S)-2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]-N-[(1S)-1-carbamoyl-2-phenylethyl]-3-(4-fluorophenyl)propanamide
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC30H34FN5O5
Molar mass563.630 g·mol−1
3D model (JSmol)
  • C[C@H](C(=O)N[C@@H](CC1=CC=C(C=C1)F)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
  • InChI=1S/C30H34FN5O5/c1-18(34-29(40)24(32)15-20-9-13-23(37)14-10-20)28(39)36-26(17-21-7-11-22(31)12-8-21)30(41)35-25(27(33)38)16-19-5-3-2-4-6-19/h2-14,18,24-26,37H,15-17,32H2,1H3,(H2,33,38)(H,34,40)(H,35,41)(H,36,39)/t18-,24+,25+,26+/m1/s1
  • Key:GTPHQORJKFJIRB-JTQLPTLWSA-N

Frakefamide (INN) is asynthetic,fluorinated linear tetrapeptide with theamino acid sequence Tyr-D-Ala-(p-F)Phe-Phe-NH2 which acts as aperipherally-specific,selectiveμ-opioid receptoragonist.[1][2] Despite its inability to penetrate theblood-brain-barrier and enter thecentral nervous system,[1] frakefamide haspotentanalgesic effects and, unlike centrally-acting opioids likemorphine, does not producerespiratory depression, indicating that itsantinociceptive effects are mediated by peripheral μ-opioid receptors.[1][3] It was under development for the treatment ofpain byAstraZeneca andShire but was shelved afterphase IIclinical trials.[4][5]

See also

[edit]

References

[edit]
  1. ^abcModalen ÅÖ, Quiding H, Frey J, Westman L, Lindahl S (March 2005)."A novel molecule (frakefamide) with peripheral opioid properties: the effects on resting ventilation compared with morphine and placebo".Anesthesia and Analgesia.100 (3):713–717.doi:10.1213/01.ANE.0000145011.75545.C5.PMID 15728057.S2CID 23249323.
  2. ^Aronson JK (30 November 2009).Meyler's Side Effects of Analgesics and Anti-Inflammatory Drugs. Elsevier. p. 84.ISBN 978-0-444-53273-2. Retrieved27 April 2012.
  3. ^Modalen AO, Quiding H, Frey J, Westman L, Lindahl S (January 2006)."A novel molecule with peripheral opioid properties: the effects on hypercarbic and hypoxic ventilation at steady-state compared with morphine and placebo".Anesthesia and Analgesia.102 (1):104–109.doi:10.1213/01.ANE.0000184254.85567.80.PMID 16368813.S2CID 40297091.
  4. ^Anderson NG (15 April 2012)."Introduction".Practical Process Research and Development: A Guide for Organic Chemists. Academic Press. p. 4.ISBN 978-0-12-386537-3. Retrieved27 April 2012.
  5. ^Schmidt WK (13 May 2003)."An overview of current and investigational drugs for the treatment of acute and chronic pain". In Bountra C, Munglani R, Schmidt WK (eds.).Pain: Current Understanding, Emerging Therapies, And Novel Approaches To Drug Discovery. CRC Press. p. 400.ISBN 978-0-8247-8865-0. Retrieved27 April 2012.
Opioids
Opiates/opium
Semisynthetic
Synthetic
Paracetamol-type
NSAIDs
Propionates
Oxicams
Acetates
COX-2 inhibitors
Fenamates
Salicylates
Pyrazolones
Others
Cannabinoids
Ion channel
modulators
Calcium blockers
Sodium blockers
Potassium openers
Myorelaxants
Others
μ-opioid
(MOR)
Agonists
(abridged;
full list)
Antagonists
δ-opioid
(DOR)
Agonists
Antagonists
κ-opioid
(KOR)
Agonists
Antagonists
Nociceptin
(NOP)
Agonists
Antagonists
Others
Retrieved from "https://en.wikipedia.org/w/index.php?title=Frakefamide&oldid=1244147297"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp